Skip to main content
. Author manuscript; available in PMC: 2015 Nov 1.
Published in final edited form as: Clin Pharmacol Ther. 2014 Jul 28;96(5):589–598. doi: 10.1038/clpt.2014.158

Figure 4. Simulated serum ALT and viable liver mass in susceptible individuals.

Figure 4

In human SimPops administered 400 (A) or 600 (B) mg/day troglitazone (TGZ) for 6months, individuals with serum ALT elevations > 3× ULN (n=10 at 400mg/day; n=17 at 600mg/day) are presented. One individual at 400mg/day and two individuals at 600mg/day lost >85% of viable liver mass and was classified as dead.